Shares of Vijaya Diagnostics Ltd. surged as much as 7% after a brief dip in response to its June quarter results on Monday, June 28.The company’s revenue growth for the quarter stood at 20.4% from last year to ₹188 crore, while its Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter stood at ₹73.5 crore from ₹61 crore last year, implying a growth of 20% from last year.
EBITDA margin for the quarter stood at 39%, which is the same level which was reported during the June quarter last year.
Net profit for the period also increased by 22.4% from the year-ago quarter to ₹38.3 crore.For the June quarter, the total tests conducted increased by 16.7% from last year, while total footfalls increased by 14.4% year-on-year.
EBITDA margin for the quarter stood at 39%, which is the same level which was reported during the June quarter last year.
Net profit for the period also increased by 22.4% from the year-ago quarter to ₹38.3 crore.For the June quarter, the total tests conducted increased by 16.7% from last year, while total footfalls increased by 14.4% year-on-year.
The Average Realisation Per Footfall increased by 5.3% from last year and 3.1% from the March quarter to ₹1,707.
“We remain optimistic about achieving break-even across all centres within the 12 months with 1 hub centre in Bengaluru on track to reach break-even earlier than the estimated timeline,” MD & CEO Suprita Reddy said.
Shares of Vijaya Diagnostics are trading 5.8% higher at ₹1,133.1. The stock trades close to its 52-week high of ₹1,275, having gained 7% so far this year.
